Healthcare of Ontario Pension Plan Trust Fund Sells 29,642 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Healthcare of Ontario Pension Plan Trust Fund trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 5.6% in the third quarter, Holdings Channel reports. The institutional investor owned 498,500 shares of the company’s stock after selling 29,642 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Hims & Hers Health were worth $9,182,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in HIMS. Renaissance Technologies LLC raised its position in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares in the last quarter. State of Michigan Retirement System grew its stake in shares of Hims & Hers Health by 177.8% during the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after buying an additional 320,000 shares during the last quarter. Carnegie Investment Counsel purchased a new position in shares of Hims & Hers Health in the third quarter worth about $5,531,000. Bank of New York Mellon Corp lifted its stake in shares of Hims & Hers Health by 67.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after acquiring an additional 273,473 shares during the last quarter. Finally, Panagora Asset Management Inc. boosted its holdings in Hims & Hers Health by 246.2% during the 2nd quarter. Panagora Asset Management Inc. now owns 378,192 shares of the company’s stock valued at $7,636,000 after acquiring an additional 268,949 shares during the period. 63.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This trade represents a 84.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,343 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the sale, the insider now owns 165,254 shares in the company, valued at approximately $4,941,094.60. This trade represents a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,153,519 shares of company stock worth $24,486,721 in the last three months. 17.71% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $20.71.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $32.22 on Friday. The stock has a market cap of $7.04 billion, a PE ratio of 73.23 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The firm has a fifty day moving average price of $22.01 and a 200-day moving average price of $19.86.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.04) earnings per share. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.